title: Radiotherapy.
abstract: Solitary plasmocytoma occurring in bone (solitary plasmocytoma of the bone, SBP) or in soft tissue (extramedullary plasmocytoma, EP) can be treated effectively and with little toxicity by local radiotherapy. Ten-year local control rates of up to 90% can be achieved. Patients with multiple myeloma often suffer from symptoms such as pain or neurological impairments that are amenable to palliative radiotherapy. In a palliative setting, short treatment schedules and lower radiation doses are used to reduce toxicity and duration of hospitalization. In future, low-dose total body irradiation (TBI) may play a role in a potentially curative regimen with nonmyeloablative conditioning followed by allogenic peripheral blood stem cell transplantation.
authors.affiliation: Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. sonja.krause@med.uni-heidelberg.de
authors.forename: Sonja
authors.initials: S
authors.lastname: Krause
authors.forename: Jürgen
authors.initials: J
authors.lastname: Debus
authors.forename: Dirk
authors.initials: D
authors.lastname: Neuhof
mesh_terms: D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000532:radiotherapy*; D010146:Pain / Q000209:etiology / Q000532:radiotherapy; D010166:Palliative Care; D010954:Plasmacytoma / Q000150:complications / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D014916:Whole-Body Irradiation